Jefferies upgraded its rating to buy from hold, while Truist boosted its price target and RBC upped its target price for AdaptHealth.
3 reports, 2 independent
Updated Jul 28
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jefferies upgraded its rating to buy from hold, while Truist boosted its price target and RBC upped its target price for AdaptHealth.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AdaptHealth
health care services
-
Jefferies Financial Group
American financial services company
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
- MarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
-
Royal Bank of Canada
financial institution in Canada
Related events
- RBC and Truist Financial issued rating updates and price targets for LINE.
- MarketBeat provided consensus ratings and target prices, while Jefferies Financial Group reaffirmed a hold rating on Target Healthcare REIT.
- TD Cowen increased its target price to $3.00, while Jefferies Financial Group was involved in a rating update for Plug Power, with MarketBeat aggregating the consensus data.
- Jefferies Financial Group boosted its target price and gave a 'buy' rating for Five Below, Inc.
- MarketBeat reports average rating and target price for SS&C Technologies, while RBC boosts targets and Jefferies reduces its price objective.
Coverage
Newest first; wire copies grouped- themarketsdaily.comEnterprise Products Partners (NYSE:EPD) Trading Up 1.4% – Still a Buy?
- tickerreport.com